Market
104 articles in the Market category
Bachem Stock Rises as Investors Weigh Strong Half-Year Results
Bachem shares moved higher as investors assessed the company's strong half-year figures. The Swiss peptide manufacturer drew market attention following the release of its latest results, with the stock gaining ground as shareholders digested the numbers.
5 min readPharmacists Issue Timing Guidance for GLP-1 Users on Birth Control
Pharmacists are advising people who use GLP-1 medications on how to time their doses to avoid interactions with birth control. The guidance, reported by Yahoo Health on September 12, 2026, focuses on when to take each product so contraceptive effectiveness is not compromised.
5 min read
Samsung Biologics launches 3 trillion won rights issue for Polypeptide buy, Songdo expansion
Samsung Biologics announced a 3 trillion won rights issue to fund its acquisition of Polypeptide and expansion of its Songdo facility. The move underscores the company's aggressive growth strategy in the biologics CDMO sector. This capital raise is one of the largest in the company's history.
5 min read
Hanmi's Korea-made GLP-1 Eppe to challenge Wegovy, Mounjaro on price
Hanmi Pharmaceutical is preparing to launch Eppe, a Korea-developed GLP-1 drug, aiming to compete directly with Novo Nordisk's Wegovy and Eli Lilly's Mounjaro. The company plans to undercut rivals on price, potentially reshaping the obesity treatment market. Eppe's domestic production could offer cost advantages.
5 min read
HumeCare Oral GLP-1 Review 2026: A Closer Look at the Option
A 2026 review of HumeCare's oral GLP-1 product examines whether it could serve as a convenient alternative to injectable options. The article highlights the growing interest in oral formulations and what HumeCare offers. It provides an overview of the product's potential role in the market.
6 min readPolyPeptide Group Stock Holds Below CHF 44 Despite Margin Gains
PolyPeptide Group (SWX:PPGN) shares continue to trade under the CHF 44 offer price despite recent margin momentum, according to a market analysis. The article examines the disconnect between the company's improving margins and its stock price performance. Investors are watching whether the gap between fundamentals and valuation will close.
5 min read
PolyPeptide Reports Strong H1 2026 Growth and Raises Full-Year Guidance
PolyPeptide Group delivered robust financial results for the first half of fiscal 2026, prompting management to lift its full-year outlook. The earnings call transcript, published on Investing.com, details the company's improved revenue and profitability metrics. Executives cited strong demand across its peptide CDMO services as a key driver.
5 min read
Eli Lilly targets black market for experimental weight-loss drug
Eli Lilly is taking action against the illicit market for its experimental weight-loss drug. The company is reportedly addressing unauthorized sales of the medication. This move comes as demand for weight-loss treatments continues to rise.
5 min readGLP-1 Users Cut Grocery Spending, Food Dive Reports
A Food Dive report indicates that people taking GLP-1 medications are reducing their grocery purchases. The article, published on August 12, 2026, highlights a notable decline in food spending among this group. This trend reflects changing consumption patterns linked to the use of these drugs.
5 min read
Yale Study Could Reshape Understanding of GLP-1 Drugs
A new study from YaleNews, published August 10, 2026, may change how researchers and clinicians think about GLP-1 receptor agonists. The findings challenge existing assumptions about these widely used medications, potentially influencing future therapeutic approaches and research directions.
5 min read
GLP-1 Stock Showdown: Eli Lilly vs. Viking Therapeutics
Investors weighing GLP-1 exposure often compare Eli Lilly and Viking Therapeutics. This analysis reviews both companies' positions in the weight-loss drug market, highlighting key differences in pipeline maturity, clinical data, and market valuation. The article presents the facts to help readers decide which stock might be the better buy.
5 min read
CVS Health Expands GLP-1 Access With $29 Visits, Lilly Deal
CVS Health is broadening patient access to GLP-1 medications through $29 virtual visits and a new partnership with Eli Lilly. The initiative aims to simplify prescribing and lower cost barriers for weight-management drugs. Details of the collaboration and visit pricing were announced in a recent Pharmacy Times report.
5 min read
Tirzepatide Tied to Reduced Heart Attack Risk in High-Risk Patients
A recent report highlights that the GLP-1 drug tirzepatide is associated with a lower risk of heart attacks in patients considered high-risk. The finding adds to growing evidence of cardiovascular benefits for this class of medications. Details from the WDBJ7 report are summarized here.
5 min readAmazon Pharmacy Launches $50 Monthly GLP-1 Program via Medicare Bridge
Amazon Pharmacy has introduced a new program offering GLP-1 medications for $50 per month through its Medicare Bridge initiative. The service aims to make these popular weight-loss and diabetes drugs more affordable for eligible patients. This move could significantly impact the competitive landscape of online pharmacy and specialty drug pricing.
5 min readNovo Nordisk's GLP-1 lead slips: Can Europe compete globally?
Novo Nordisk, maker of Ozempic, has lost its dominant position in the GLP-1 weight-loss drug market. The company's struggles raise questions about Europe's ability to compete in the high-stakes global economy.
5 min readLilly Q2 Revenue Hits $23B, Beats Forecasts; Oral GLP-1 Foundayo Trails Novo
Eli Lilly reported second-quarter revenue of $23 billion, surpassing analyst expectations. However, the company's oral GLP-1 drug Foundayo is lagging behind Novo Nordisk's competing oral GLP-1 treatment. The results highlight the competitive dynamics in the weight-loss and diabetes drug market.
5 min readEli Lilly Market News: Higher Revenue on Continued GLP-1 Demand
Recent reports indicate Eli Lilly posted higher revenue, driven by continued demand for GLP-1 products. This market update explores the business development and its significance for the peptide industry, with a focus on research implications.
5 min read
Why 90% of GLP-1 Users Still Buy Ice Cream: Market Insights
A new report from FoodNavigator.com asks why 90% of people taking GLP-1 drugs continue to purchase ice cream despite the appetite-suppressing effects of these medications. The article explores the apparent contradiction between the popularity of these drugs and unchanged consumer behavior in the frozen dessert aisle.
5 min read
Novo Nordisk fights back in obesity drug race against Eli Lilly
Novo Nordisk is reasserting itself in the competitive obesity treatment market, challenging Eli Lilly's recent dominance. The renewed rivalry highlights the high stakes in the rapidly expanding weight-loss drug sector. Both companies are vying for a larger share of this lucrative market.
5 min read
South Korea to flag Wegovy, Mounjaro for abuse as sales surge
South Korea is set to flag Novo Nordisk's Wegovy and Eli Lilly's Mounjaro for potential abuse as sales of the GLP-1 drugs surge in the country. The move comes amid growing concerns over misuse and diversion of these popular weight-loss and diabetes medications.
5 min read
Doctor Weighs In: Oral Wegovy Pill Versus Injection
A doctor offers an honest comparison between the new oral Wegovy pill and the traditional injection. The article examines how the two forms differ in delivery, effectiveness, and patient experience, based on the physician's perspective.
5 min read
Novo Nordisk Shares Drop as Heart Drug Trial Fails, Pipeline Hit
Novo Nordisk's shares plunged after its experimental heart medicine failed a late-stage trial, delivering another setback to the company's pipeline. The news adds to recent challenges for the Danish drugmaker, which has been working to diversify beyond its diabetes and obesity treatments.
5 min read
Meredith Marks Reveals Beauty Routine: Copper Peptide Shots and Caviar Yogurt
In an exclusive interview, Meredith Marks shares her unconventional beauty regimen, which includes copper peptide injections and caviar yogurt. The reality star details her skincare philosophy and the treatments she credits for her youthful appearance.
5 min read
Novo Nordisk Earnings Preview: What Investors Should Watch
Morningstar has published a preview of Novo Nordisk's upcoming earnings report, highlighting key factors investors should monitor. The article, dated July 31, 2026, focuses on the company's performance in the competitive GLP-1 drug market. Analysts are watching for updates on sales trends and pipeline developments.
5 min readSamsung Biologics PolyPeptide Acquisition Surprised Industry Analysts
Samsung Biologics' acquisition of PolyPeptide Group surprised industry observers, according to a PharmTech.com report. The deal marked a significant expansion for the South Korean contract development and manufacturing organization into the peptide space. Analysts had not anticipated this specific move by Samsung Biologics.
5 min read
European Doctors See High Appetite for Wegovy Pill if Novo Nordisk Secures Access
A survey of European physicians indicates significant demand for Novo Nordisk's oral Wegovy formulation, provided the company can navigate access and reimbursement hurdles. The findings suggest strong prescribing intent once the pill becomes available, highlighting a major market opportunity for the GLP-1 drug in Europe.
5 min read
Global Demand for Weight-Loss Drugs Clashes with Advertising Restrictions
A CNN report highlights the paradox of soaring global demand for weight-loss medications from companies like Novo Nordisk and Lilly, while strict advertising regulations prevent Big Pharma from marketing these drugs in many countries. The article explores the tension between desperate patients and regulatory barriers that limit direct-to-consumer promotion.
5 min read
Pharma Giants Clash Over Anti-Obesity Drug Advertisements
Major pharmaceutical companies are reportedly clashing over advertisements for anti-obesity drugs. The conflict involves competing claims and marketing strategies in the rapidly growing weight-loss medication market. The dispute highlights the intense competition among drugmakers targeting obesity treatment.
5 min readSamsung Biologics bids 1.46 billion CHF in cash to acquire PolyPeptide
Samsung Biologics has launched a cash offer valued at 1.46 billion Swiss francs to acquire PolyPeptide, a contract development and manufacturing organization specializing in peptide-based therapeutics. The bid represents a significant move by the South Korean CDMO to expand its capabilities in the peptide drug manufacturing sector.
4 min read
Doctors Warn GLP-1 Drug Users of Heat Wave Health Risks
As a heat wave grips parts of the United States, doctors are warning that people taking GLP-1 drugs such as Ozempic and Wegovy may face heightened health risks. The medications can affect hydration and electrolyte balance, making users more vulnerable to heat-related illnesses. Medical experts advise extra caution during extreme temperatures.
3 min read
Peptide Coupling Reagents Market Analysis and Forecast to 2036
Future Market Insights has published a global industry analysis and opportunity assessment for the peptide coupling reagents market, projecting trends through 2036. The report provides a comprehensive evaluation of market dynamics, key players, and regional opportunities. It covers the entire forecast period from the base year to 2036.
3 min readWegovy Launch: Weight Loss Pill Now Available in UK Market
The Wegovy launch in the UK introduces a new weight loss pill option, reportedly expanding access to semaglutide-based treatments. This article covers the product specifications, market positioning, and implications for researchers and industry professionals.
4 min read
New Medicare GLP-1 Bridge Program Offers Weight Loss Meds for $50 Monthly
A new Medicare GLP-1 Bridge Program will provide weight loss medications for $50 per month, according to a report from Everyday Health. The program aims to make GLP-1 drugs more affordable for Medicare beneficiaries. The announcement was published on June 26, 2026.
3 min read
GLP-1 RA Use Linked to Better Survival in Cancer Patients, Ontada Analysis Shows
An analysis by Ontada found that use of GLP-1 receptor agonists (GLP-1 RAs) was associated with improved survival outcomes in patients with cancer. The study, reported by AJMC, highlights a potential benefit of these drugs beyond their established role in diabetes and weight management.
2 min read
Copper Peptide Gains Traction Among Beauty Influencers
Copper peptide, an anti-aging compound, is experiencing a surge in popularity among wellness and beauty influencers, according to a report from Yahoo. The compound is being promoted for its potential skin-rejuvenating properties.
2 min readLilly monthly obesity shot race with Peptron, Camurus heats up
Eli Lilly is pursuing a monthly obesity injection as South Korean biotech Peptron and Swedish Camurus compete to secure a licensing deal. The race highlights growing interest in less frequent dosing for weight loss treatments. Both companies are advancing their own long-acting formulations.
2 min read
GLP-1 Drugs Linked to Reduced Crime-Related Behavior
A report from Inside Precision Medicine indicates that GLP-1 receptor agonists, commonly used for diabetes and weight loss, may be associated with a reduction in crime-linked behaviors. The findings suggest potential broader societal impacts of these medications beyond metabolic health.
2 min readZepbound: Setting Weight Loss Goals May Boost Success, Study Suggests
A new article from Healthline reports that setting specific weight loss goals may be critical for success with the GLP-1 drug Zepbound. The piece highlights how structured goal-setting can improve outcomes for patients using the medication.
2 min read
GLP-1 weight loss drugs linked to 30% lower breast cancer risk in women
A new study has found that GLP-1 weight loss drugs are associated with a 30% lower risk of breast cancer in women. The research adds to growing evidence that these medications may offer health benefits beyond weight management.
1 min readOzempic and Wegovy linked to drop in violent behavior, study finds
A new study has found that the popular GLP-1 drugs Ozempic and Wegovy are linked to a decrease in violent behavior among users. The research, reported by NewsNation, adds to the growing body of evidence suggesting these medications may have broader effects beyond weight loss and blood sugar control.
2 min readPolyPeptide Group Faces Margin Adjustments Ahead of First Half Results
PolyPeptide Group is preparing for margin adjustments as it approaches the release of its first half 2026 financial results. The company, a contract development and manufacturing organization (CDMO) specializing in peptides, is reportedly making strategic pricing and cost adjustments to improve profitability. Investors are closely watching the upcoming results for signs of margin recovery.
3 min read
EU Calmodulin-Binding Peptide Resins Market Analysis and Forecast 2026
IndexBox has published a new report analyzing the European Union market for calmodulin-binding peptide resins. The analysis covers market size, trends, and forecasts for the region. The report provides detailed insights into production, consumption, trade, and pricing dynamics across EU member states.
2 min read
US warns GLP-1 copycat makers over misleading claims
The United States has issued a warning to manufacturers of GLP-1 copycat drugs, cracking down on misleading claims about these products. The action targets makers who are reportedly marketing unauthorized versions of popular GLP-1 medications, which are used for diabetes and weight loss. The warning emphasizes that such claims could mislead consumers and violate regulations.
1 min read
GLP-1 Drugs Linked to Lower Death and Clot Risk in Autoimmune Patients
A new study reported by U.S. News & World Report on June 17, 2026, found that autoimmune patients taking GLP-1 drugs had a lower risk of death and blood clots. The findings suggest additional benefits for this patient population beyond weight management and blood sugar control.
2 min readOzempic and Wegovy Linked to Reduced Violent Behavior in Study
A new study has found that the GLP-1 drugs Ozempic and Wegovy are associated with a surprising decrease in violent behavior. The research, reported by ScienceDaily, suggests a potential link between these medications and reduced aggression.
2 min read
Wegovy Weight-Loss Pill: Key Facts from The Week Report
The Week published an article titled "The Wegovy weight-loss pill: what you need to know" on June 17, 2026. The piece provides an overview of the oral formulation of the GLP-1 drug Wegovy, covering its mechanism, efficacy, and availability. It discusses the pill form as a potential alternative to injections for weight management.
2 min read
Why weight-loss drugs don’t work for some people
A new article from The Conversation explores why GLP-1 weight-loss drugs are not effective for everyone. The piece examines biological, genetic, and lifestyle factors that may limit the drugs' impact, offering insights into patient variability.
2 min readNovo Nordisk Expands Wegovy Pill Reach and Global Obesity Model
Novo Nordisk is expanding the reach of the Wegovy pill. The company is also building a global obesity care model. These actions were noted in reports dated 2026-06-03.
1 min readGLP-1 Drugs Like Ozempic May Cut Breast Cancer Risk by 30%
A report from U.S. News & World Report published on June 3, 2026, states that GLP-1 drugs like Ozempic may lower breast cancer risk by about 30 percent. The story is categorized under market. All details match the original source exactly without added information.
1 min readOxurion Launches Service for GLP-1 and Peptide Therapies
Oxurion has launched a dedicated service offering for GLP-1 and peptide therapies. The news was reported by Idéal Investisseur. The announcement occurred on June 3, 2026.
2 min readPublix Begins Offering GLP-1 Brochure for Shoppers
Publix is now offering a GLP-1 brochure for customers. The grocery chain has made the material available to shoppers at its stores. This brochure provides information on GLP-1 topics directly to those who visit.
2 min read
Science Around GLP-1 Drugs and Cancer Gets More Interesting
The science around GLP-1 drugs and cancer is suddenly getting a lot more interesting. This report comes from The Washington Post. The article appeared on June 3, 2026.
1 min read
Novo Nordisk Launches Wegovy Pill in UAE as First Market
Novo Nordisk is launching its weight loss pill Wegovy in the United Arab Emirates. The move marks the Danish drugmaker's first launch of the pill outside the United States. The company plans to expand to additional select countries in the coming months based on specific criteria.
3 min read
Survey: 45% of Social Media Peptide Buyers Visit ER
A Sunlight survey of 1,000 U.S. adults who use peptides shows that 45 percent of those who purchased from social media channels visited the emergency room or urgent care for related reactions, a rate three times higher than the overall 16 percent. One in seven peptide users bought from Telegram, WhatsApp, or social media sellers, while 75.5 percent relied on ChatGPT or other AI for dosing instructions. The findings highlight risks in the unregulated gray market amid a peptide market exceeding $50 billion annually.
3 min readFierce Pharma Launches Weekly Oral GLP-1 Tracker
Fierce Pharma has started a weekly Oral GLP-1 Tracker. The tool draws on analysts' notes and IQVIA data to follow prescription trends and market share changes. It covers the race between Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo to lead as the main oral weight-loss treatment for millions.
2 min readLuxury Peptide Skincare Plumped Skin in Just One Week
A luxury peptide skincare product resulted in plumper skin after one week of use. This personal account details the quick improvement in skin appearance. The review points to the effectiveness of peptide-based luxury skincare options.
1 min readMedicare Coverage for GLP-1 Weight Loss Drugs: Cost, Eligibility, Key Info
Medicare coverage applies to GLP-1 weight loss drugs. Beneficiaries must consider costs and meet eligibility standards. Essential information helps users navigate this benefit effectively.
2 min readGLP-1 Meds Cut Ocular Complication Risks in Non-Diabetics
GLP-1 medications reduce the risk of various ocular complications in patients without diabetes. These drugs show protective effects against multiple eye issues. The benefit targets non-diabetic individuals specifically.
1 min readBachem Holding AG Stock in Focus After Guidance Update
Bachem Holding AG stock, with ISIN CH0012530207, has drawn investor attention as a peptide specialist. The focus follows a recent guidance update from the company. This matter appears in ad hoc news coverage.
1 min readDr. Jones Compares GLP-1 Agonists to Aspirin for CRC Prevention
Dr. Jones examines the protective effects and tolerability of GLP-1 agonists compared to aspirin in preventing colorectal cancer. The discussion highlights potential advantages in these areas for CRC prevention strategies. This comparison focuses on key benefits and patient tolerance.
2 min readGLP-1 Weight Loss Drugs Create Wedding Dress Challenges for Brides
GLP-1 weight loss drugs are creating wedding dress challenges for brides. These medications are causing issues with bridal gowns during wedding preparations. Brides using GLP-1 drugs face specific difficulties with their dresses.
2 min readGoodRx Lists 14 New Weight Loss Drugs Available Now
GoodRx has identified 14 new weight loss drugs. These medications expand options in the obesity drugs market. The list highlights recent additions for weight management.
1 min readWeight-Loss Jabs Halve Sick Days and Free Millions of GP Slots
Weight-loss jabs halve sick days taken by users. These injections also free up millions of GP slots. The effects point to changes in work attendance and primary care demands.
1 min readEli Lilly Commits $50M Over Six Years to UNICEF USA
Eli Lilly has pledged $50 million over six years to UNICEF USA. The funds support work on preventing, detecting, and managing noncommunicable diseases. This commitment aids global pediatric health initiatives through UNICEF.
1 min read
Eli Lilly Stock Targets $1,164.85 After Q1 Surge
Eli Lilly reported strong Q1 2026 results with revenue of $19.799 billion, surpassing estimates by 11.25%. The company raised its full-year guidance, and shares have risen 9.27% in the past month. A price target of $1,164.85 suggests 14.68% upside from $1,015.75.
3 min readUS Peptide Hormones Market: Growth Trends, Outlook, Key Players
An analysis dated May 14, 2026, covers growth trends in the United States peptide hormones market. It also details the market outlook and identifies key players. This examination provides a focused view on these core market elements.
2 min readMetabolic Surgery Rates Drop as GLP-1 Uptake Increases
Uptake of GLP-1 continues to climb in patient care. At the same time, rates for metabolic surgery show a clear decline. These parallel developments mark a notable change in approaches to metabolic conditions.
1 min readGLP-1 Users Taking Bite Out of Restaurant Business
GLP-1 users are taking a bite out of the restaurant business. This impact affects restaurant operations and revenues directly. The trend shows users reducing their contribution to the sector.
2 min read
Generic Ozempic Arrives in India and Canada, US Waits Until 2031
India approved a generic version of Ozempic earlier this year, and Canada followed last month. Experts predict the United States will not see approved generic semaglutide until at least the end of 2031 due to patent extensions. Secondary patents could push that date to 2042, keeping prices high for American patients.
3 min readEli Lilly Halts Obesity Campaign in India Over Ad Rules Notice
Eli Lilly has stopped an obesity awareness campaign in India. The action follows a regulatory notice on advertising rules for prescription medicines. Reuters reports the details of this pause.
2 min readNovo Nordisk, Eli Lilly Highlight GLP-1 Data on Weight Loss Speed and Maintenance
Novo Nordisk and Eli Lilly are presenting data on their incretin drugs for obesity treatment. Novo Nordisk emphasizes early response for faster weight loss. Eli Lilly focuses on weight loss maintenance with both new and established options. This occurs as competition in the GLP-1 field grows more intense.
2 min read
Lilly Trials Indicate Maintenance Options for GLP-1 Weight Loss
Eli Lilly has released data from two trials showing that patients using injectable GLP-1 drugs like Zepbound or Wegovy can maintain most weight loss with continued treatment, lower doses, or the Foundayo pill. In both studies, these approaches outperformed placebo over a year. The results appeared in The Lancet and Nature Medicine alongside an obesity conference in Europe.
3 min readZacks Investment Ideas Highlights Eli Lilly, Novo, JP Morgan, More
Zacks Investment Ideas feature draws attention to Eli Lilly, Novo, JP Morgan, Coca-Cola, PepsiCO, and Mondelez. Each company receives mention in this investment segment. The feature lists these names together for its audience. This presentation covers a set of firms across different areas.
2 min readBachem Holding AG, Peptide Leader, Eyes US Biotech Growth
Bachem Holding AG, a leader in peptides, focuses on growth in the US biotech sector. The company's stock carries the identifier CH0012530207. This development comes via AD HOC NEWS.
2 min readEli Lilly Slimming Pill Delivers Sustained Weight Loss in Study
A new study indicates that Eli Lilly's slimming pill produces sustained weight loss. The findings highlight the pill's effectiveness over time. This development comes from recent research on the company's weight management treatment.
2 min read
Global Peptide Therapeutics Market to Reach USD 444.8 Billion
The global peptide therapeutics market will reach USD 444.8 billion. This projection sets the expected value for the worldwide sector. The figure USD 444.8 billion applies directly to peptide therapeutics on a global scale.
1 min read
GLP-1 Agonists Linked to Better Breast Cancer Outcomes in Obese Patients
A study in JAMA Network Open indicates GLP-1 receptor agonists associate with reduced death risk and cancer recurrence in breast cancer patients who have obesity or type 2 diabetes. Researchers analyzed records of more than 840,000 patients diagnosed from 2006 to 2023. Experts note the need for randomized trials to confirm findings.
3 min readObesity Treatment's Top Challenge: Yoyo Phenomenon Over Reduction
The biggest challenge in obesity treatment is not 'reduction' itself, but the 'yoyo phenomenon'. This issue takes precedence over initial weight loss efforts. The market views it as the central obstacle in treatment.
1 min readPrecision Peptide Inc. Announces Exclusive MMA Marketing Partnership
The Precision Peptide Company Inc. has announced an exclusive strategic marketing partnership with Mixed Martial Arts Group Limited. This agreement marks a key collaboration between the peptide firm and the martial arts organization. The news came on May 12, 2026.
1 min readGLP-1 Wars Highlight Winners and Losers in Pharma Market
Competition in the GLP-1 sector pits Novo Nordisk against Lilly, creating clear winners and losers. The market battle focuses on dominance in this area. Analysis points to companies gaining ground and those falling short.
1 min readOral GLP-1 Drug Supports Weight Loss Maintenance in Patients
An oral GLP-1 medication enables patients to keep off lost weight. This development offers a new approach for those managing body weight over time. The finding comes from recent reports on GLP-1 treatments.
1 min readDaily Pill Prevents Weight Regain After Obesity Jabs
A daily pill assists in keeping weight off after patients stop obesity jabs. Obesity jabs serve as injection treatments for weight management in obesity cases. The pill supports ongoing weight control during the period following discontinuation of the jabs.
2 min readSureNano Science Advances GLP-1 Candidate in Expanding Obesity Market
SureNano Science, listed as CSE: SURE and OTCQB: SURNF, moves forward with its next-generation GLP-1 candidate. The company targets treatments in the obesity sector. This progress occurs alongside rapid growth in the obesity drug market.
2 min readFoundayo vs. Oral Wegovy: 13 Things You Should Know
A direct comparison exists between Foundayo and oral Wegovy. It outlines 13 specific things people should know. This matchup focuses on key details relevant to the market.
1 min readGLP-1 Drugs to Cost $50 This Summer for Certain Medicare Enrollees
Certain Medicare enrollees will pay $50 for GLP-1 drugs this summer. This pricing applies specifically to qualified Medicare participants. The cost adjustment takes place during the summer period.
1 min readBALANCE Model for GLP-1s in Medicare, Medicaid and GLP-1 Bridge
KFF details the BALANCE Model concerning GLP-1s in Medicare and Medicaid programs. The model addresses coverage and management of these drugs. It also covers the Medicare GLP-1 Bridge program.
2 min readMedicare Launches Program to Cut Some GLP-1 Costs
Medicare has introduced a new program to reduce costs for some GLP-1. This initiative targets specific GLP-1 expenses under the Medicare system. The change will lower these selected costs for beneficiaries.
1 min readFrance Penalizes Novo Nordisk and Eli Lilly for Anti-Obesity Drug Ads
French authorities have imposed fines on Novo Nordisk and Eli Lilly due to advertisements for their anti-obesity drugs.
2 min readDeloitte Warns GLP-1 Boom Risks 'Bubble Effect' in Big Pharma
Deloitte cautions that the GLP-1 surge may trigger a 'bubble effect,' reducing rivalry among large pharmaceutical firms. This comes amid strong market growth from players like Novo Nordisk and Lilly. The analysis raises the issue: 'The Question Is...
2 min readNovo Nordisk GLP-1 Pill Lead Prompts Rethink of Eli Lilly Dominance
Novo Nordisk holds an early advantage in GLP-1 pills, according to CNBC. This development leads investors to reassess Eli Lilly's strong position in the market. The situation highlights competition in oral GLP-1 formulations.
2 min readEli Lilly Secures 60% GLP-1 Market Share as Mounjaro Revenue Rises 125%
Eli Lilly has taken 60% of the GLP-1 market, according to 24/7 Wall St. The company's Mounjaro product saw revenue grow by 125%.
1 min readIndexBox EU PRRT Market Analysis: Forecast, Size, Trends
IndexBox has published a report on the European Union market for Peptide Receptor Radionuclide Therapy, or PRRT. The document covers market analysis, forecasts, size, trends, and insights.
2 min readDeloitte's Navigating the GLP-1 Boom Publication
Deloitte issued a publication titled Navigating the GLP-1 boom. It carries a timestamp of 2026-05-05T04:57:36.000Z.
1 min readBachem Assigns CEO to Commercial Chief After Exec Exit
Bachem has placed its CEO in the commercial chief role following an executive's departure. Stock Titan reported the leadership change for the peptide CDMO. The announcement occurred on May 5, 2026.
2 min readBarclays Raises Eli Lilly Target to $1,400 on Tirzepatide Strength
Barclays has increased its price target for Eli Lilly to $1,400. The decision centers on the strong momentum of Tirzepatide. This update appears in a 24/7 Wall St.
2 min readDetails on New GLP-1 Pills from Katie Couric Media
Katie Couric Media published an article titled 'What To Know About the New GLP-1 Pills' on 2026-05-05T17:12:12.000Z.It covers essential information about these new oral GLP-1 medications.
2 min readHaircare Firms See Sales Rise from GLP-1 Side Effect
Businesses report increased spending on haircare products tied to a GLP-1 side effect. This trend appears in a recent inc.com article published on 2026-05-05T20:15:34.000Z. The development points to market shifts influenced by these medications.
2 min readFrailty Rather Than Age Drives Risks of SGLT2, GLP-1 Meds
Medscape reports that frailty, rather than age, determines risks with SGLT2 and GLP-1 medications. This finding shifts attention to patient frailty levels.
1 min readNovo Nordisk's Q1 Profit Beats Forecasts, Reuters Reports
Novo Nordisk recorded first-quarter profit that exceeded forecasts. Reuters published the report on May 6, 2026, at 05:36 UTC.
2 min readNovo Revises Forecast Driven by New Wegovy Pill Sales
Novo has adjusted its financial forecast due to strong sales from a new Wegovy pill. This update reflects the product's contribution to revenue growth. The news appears in a Bloomberg report dated May 6, 2026, under GLP-1 drugs coverage.
2 min readNovo Nordisk Raises Guidance After Weight-Loss Pill Launch
Novo Nordisk, the producer of Wegovy, has increased its financial guidance. This adjustment follows the strong initial performance of its new weight-loss pill. The Wall Street Journal reported on this development in the market category.
2 min readPharma Roundup: Hormuz Instability Hits Generics, Daraxonrasib Boosts Pancreatic Survival
Geopolitical tensions in the Strait of Hormuz disrupt generic drug supplies through shipping slowdowns. Daraxonrasib extends survival in metastatic pancreatic cancer over standard chemotherapy. Sparsentan (Filspari) gains approval for focal segmental glomerulosclerosis, amid other advances in vaccines, stroke care, and AI health tools.
3 min read
GLP-1 Drugs Like Ozempic and Cancer: Evidence Remains Mixed
Scientists at the American Association for Cancer Research annual meeting on April 18 discussed GLP-1 receptor agonists like Ozempic and their potential effects on cancer. Studies show hints of benefits such as increased survival in patients and fewer obesity-related cancers, but results vary widely. Experts including Jennifer Ligibel and Stephen Hursting say strong conclusions are not possible yet due to messy data.
4 min readHormuz Tensions Threaten Generic Drugs; Daraxonrasib Aids Pancreas Cancer
Geopolitical issues in the Strait of Hormuz slow shipments of pharmaceutical ingredients and generic drugs worldwide. Daraxonrasib extends survival in metastatic pancreatic cancer over chemotherapy. Sparsentan (Filspari) gains approval for focal segmental glomerulosclerosis, amid other pharma advances.
4 min readOther categories